Infection by Mycobacterium chelonae at the site of administration of sarilumab for rheumatoid arthritis

Rheumatology (Oxford). 2020 Jan 1;59(1):265. doi: 10.1093/rheumatology/kez186.

Authors

Raquel Dos Santos Sobrín¹, Nair Pérez Gómez², Alejandro Souto Vilas¹, Manuel Pombo Suárez¹, Eva Pérez Pampín¹, Jose Ramón Antúnez López³, Antonio Mera Varela¹

Affiliations

¹ Rheumatology Department, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
² Rheumatology Department, Clinical University Hospital of Vigo, Vigo, Spain.
³ Pathology Department, Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.

PMID: 31106373
DOI: 10.1093/rheumatology/kez186

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage*
Arthritis, Rheumatoid / drug therapy*
Diagnosis, Differential
Female
Humans
Injections, Intramuscular / adverse effects
Middle Aged
Mycobacterium Infections, Nontuberculous / diagnosis
Mycobacterium Infections, Nontuberculous / etiology*
Mycobacterium Infections, Nontuberculous / microbiology
Mycobacterium chelonae / isolation & purification*
Opportunistic Infections*
Skin / microbiology
Skin / pathology*
Skin Diseases, Bacterial / diagnosis
Skin Diseases, Bacterial / etiology*
Skin Diseases, Bacterial / microbiology
Umbilicus

Substances

Antibodies, Monoclonal, Humanized
sarilumab